Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease.

16 Apr 2010

High sensitivity of Zetasizer Nano proves essential for protein aggregation studies

Dr Martin Muschol, Assistant Professor at the University of South Florida’s (USF) Department of Physics and his team are carrying out important research to gain a better understanding of protein aggregation phenomena, including protein crystallization and amyloid fibril growth. Using the Zetasizer Nano ZS, from Malvern Panalytical (Malvern Panalytical, UK), the USF researchers have been able to perform temperature controlled static and dynamic light scattering (DLS) measurements of protein hydration, protein interactions and aggregation kinetics in vitro.

From Malvern Panalytical 15 Apr 2010

First Edition: April 15, 2010

In today's headlines: The jobless benefits package, including a COBRA subsidy extension and Medicare-doctor pay fix, advances in the Senate. In the House, a committee chairman cancels a hearing on business health care complaints.

15 Apr 2010

EU Joint Programming initiative to tackle neurodegenerative diseases

Leading researchers from across Europe will gather today in Stockholm to develop a European-wide research strategy to tackle neurodegenerative diseases such as Alzheimer's and Parkinson's Disease.

15 Apr 2010

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

Pseudobulbar affect (PBA) is a neurologic condition of involuntary, sudden and frequent episodes of laughing or crying and is quite common in patients with underlying neurologic diseases or injuries, especially those with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

15 Apr 2010

GBS cases reduce following 2009 H1N1 vaccination: Research study

A new study finds that reports of a neurologic disease called Guillain-Barré syndrome have been low after 2009 H1N1 vaccination, according to a research study that will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today offered additional commentary, clarifications and insights on yesterday's announcement of its Phase IIa clinical results of Serdaxin® in the treatment of major depressive disorder (MDD).

15 Apr 2010

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and significantly reduced the rate of atrophy (shrinkage) of their brains, according to a study performed at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

15 Apr 2010

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Avid Radiopharmaceuticals, Inc. today announced the presentation of interim data from its landmark florbetapir "Image-to-Autopsy" Phase III study. These data come from the first cohort of subjects in the trial and are the first ever Phase III results for an agent designed to image Alzheimer's disease pathology.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

Researchers identify gene that appears to increase risk of Alzheimer's disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common type of Alzheimer's disease. The research will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

Study: New anti-cancer agents halt cancer metastasis

ke microscopic inchworms, cancer cells slink away from tumors to travel and settle elsewhere in the body. Now, researchers at Weill Cornell Medical College report in today's online edition of the journal Nature that new anti-cancer agents break down the loping gait these cells use to migrate, stopping them in their tracks.

15 Apr 2010

Foods that protect from Alzheimer’s

In a recent study researchers have revealed what we always knew - salads, fish, fruits and nuts are good for us. It says that these food combinations are related to a reduced risk of getting the dreaded brain and memory disease called Alzheimer’s disease. This study published in the online edition of the reputed journal Archives of Neurology also says that lesser the amount of high-fat dairy foods like butter etc. and red meats, the lesser is the risk of Alzheimer’s disease.

13 Apr 2010

Benefits of moderate alcohol drinking on stroke risk counteracted by cigarette smoking

New research finds any beneficial effect of drinking moderate amounts of alcohol on stroke may be counteracted by cigarette smoking, according to research that will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

13 Apr 2010

Researchers discover two synthetic small molecule drugs to prevent death of human stem cell

Scientists at The Scripps Research Institute have solved the decade-old mystery of why human embryonic stem cells are so difficult to culture in the laboratory, providing scientists with useful new techniques and moving the field closer to the day when stem cells can be used for therapeutic purposes.

13 Apr 2010

New driving guideline for people with Alzheimer's disease

The American Academy of Neurology has issued a new guideline to help determine when people with Alzheimer's disease or another type of dementia should stop driving. The guideline is published in the April 12, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology, and was presented at the American Academy of Neurology's Annual Meeting in Toronto.

13 Apr 2010

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Enrollment completed in Impax Pharmaceuticals' APEX-PD trial of IPX066

High sensitivity of Zetasizer Nano proves essential for protein aggregation studies

First Edition: April 15, 2010

EU Joint Programming initiative to tackle neurodegenerative diseases

New investigational treatment may help prevent involuntary outbursts in MS and ALS patients

GBS cases reduce following 2009 H1N1 vaccination: Research study

Patients with RLS using rotigotine achieve sustained improvements

Rexahn Pharmaceuticals' Phase IIa clinical results of Serdaxin for MDD: Additional insights

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

New experimental compound offers hope for patients with non-Hodgkin's lymphoma

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Researchers identify gene that appears to increase risk of Alzheimer's disease

Study: New anti-cancer agents halt cancer metastasis

Foods that protect from Alzheimer’s

Benefits of moderate alcohol drinking on stroke risk counteracted by cigarette smoking

Researchers discover two synthetic small molecule drugs to prevent death of human stem cell

New driving guideline for people with Alzheimer's disease

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in